On July 31, 2022, Haddad, Fadi G.; Sasaki, Koji; Issa, Ghayas C.; Garcia-Manero, Guillermo; Ravandi, Farhad; Kadia, Tapan; Cortes, Jorge; Konopleva, Marina; Pemmaraju, Naveen; Alvarado, Yesid; Yilmaz, Musa; Borthakur, Gautam; DiNardo, Courtney; Jain, Nitin; Daver, Naval; Short, Nicholas J.; Jabbour, Elias; Kantarjian, Hagop published an article.SDS of cas: 380843-75-4 The title of the article was Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. And the article contained the following:
Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia-chromosome-pos. chronic myeloid leukemia (Ph-pos. CML) is increasingly considered. We aim to evaluate the outcome of patients with CML who discontinued TKIs, and determine the factors associated with differences in the success rates of treatment-free remission (TFR). Patients with Ph-pos. CML treated between Oct. 1999 and Feb. 2017 who discontinued therapy were analyzed. A major mol. response (MMR) was defined as BCR-ABL1/ABL1 ratio on the International Scale ≤0.1%. TFR failure was defined as the loss of MMR on any single test. We analyzed TFR rates according to duration and depth of response, and conducted a multivariate anal. for factors associated with loss of MMR. Two-hundred and eighty-four patients were analyzed; 199 patients (70%) electively discontinued TKIs. At a median follow-up of 36 mo (95% confidence interval, 32-40) after TKI discontinuation, 53 patients (19%) lost MMR. The estimated 5-yr TFR rate was 79%. All but one patient regained MMR after resuming therapy. The estimated 5-yr TFR rates were higher with MR4 and MR4.5 ≥5 years, compared with MR4 <5 years (87% vs. 92% vs. 64%; p < .0001). By multivariate anal., only the duration of MR4 or MR4.5 ≥5 years before stopping treatment was associated with a lower risk of loss of MMR. In summary, TFR is safe and feasible in patients with Ph-pos. CML on TKI therapy. Achieving MR4 or MR4.5 for at least 5 years is correlated with a better outcome. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4
The Article related to chronic myeloid leukemia tyrosine kinase inhibitor treatment free remission, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics